BTLA and esophageal squamous cell carcinoma: The BT-NICE trial is the first exploratory official report to evaluate the safety and effectiveness of neoadjuvant anti-BTLA and PD-1 combined IO-IO strategies with chemotherapy and adjuvant IO-IO strategies in the treatment of ESCC, which poses a novel challenge for the current treatment strategies.